Liquid Biopsy Explained: The Blood Test That Screens for Multiple Cancers at Once

Somewhere between "I feel fine" and "my mother, my aunt, and my grandfather all had cancer" sits a very specific kind of worry — quiet, persistent, and usually unaddressed by an annual check-up. Liquid biopsy is the technology built for exactly that gap: a single blood draw that can flag early signals of dozens of cancer types at once, long before any symptom would prompt a doctor's visit.

This article explains what liquid biopsy actually is, why so many people are asking for it, where it fits realistically alongside standard screening, and how it will soon become part of the Aeonix prevention platform.

What is a liquid biopsy?

A liquid biopsy is a blood test designed to detect biological traces that cancer cells shed into circulation — most commonly fragments of circulating tumour DNA (ctDNA), carried within the broader pool of cell-free DNA (cfDNA) that everyone's cells release into the bloodstream as they turn over. Some platforms also analyse circulating tumour cells, exosomes, or tumour-associated proteins.

The newest generation — often called multi-cancer early detection (MCED) tests — doesn't just look for one tumour type. It reads the methylation pattern stamped onto cfDNA fragments. Because different tissues and cancer types leave distinct methylation "fingerprints," a single blood sample can be screened for signals consistent with dozens of cancers simultaneously, and the pattern can often point to the likely tissue of origin — the biology behind why this is described as a "liquid" alternative to a traditional tissue biopsy.

The problem: living with the worry, not the answer

For a large share of people, the anxiety about cancer isn't abstract. It's a parent who died of pancreatic cancer at 58. A sibling's diagnosis at 45. A grandmother who had the same "type" that seems to run through the family tree. Family history is one of the strongest predictors of personal risk for several major cancers, and people who carry it often know their risk is elevated — they just don't have a practical way to do anything about that knowledge between annual check-ups.

Standard screening is real, but it's narrow by design. In most health systems, organised cancer screening exists for a handful of cancers — breast, cervical, colorectal, and in some cases lung or prostate — selected because population-level trials showed a net benefit. Everything outside that narrow list — pancreatic, ovarian, liver, kidney, many blood cancers, and dozens more — has essentially no recommended early screening test at all. Of the cancer types Galleri's PATHFINDER 2 trial detected, roughly three-quarters had no standard screening option available to the patient at all.

That leaves a large population of "worried well" — people who are healthy today, carry a family history or simply want to be proactive, and have no structured way to act on that worry beyond waiting for symptoms. Liquid biopsy was built to close exactly that gap. It is a tool for informed action, not a reason to spiral into constant testing — used well, it converts a diffuse fear into a specific, periodic check.

What standard screening still misses

There are more than 200 recognised types of cancer. Organised screening programmes, however well designed, realistically address a small fraction of them. That mismatch is the structural reason liquid biopsy has generated so much interest — it is the first practical technology aimed at the majority of cancer types that population screening does not reach.

What liquid biopsy can — and cannot — tell you

Clarity matters more here than almost anywhere else in preventive medicine, because the emotional stakes of a false result — in either direction — are high.

In the largest interventional study to date of a leading MCED blood test (GRAIL's Galleri, PATHFINDER 2, ~35,000 adults aged 50+), published results showed:

• Specificity of 99.6% — a false-positive rate of roughly 0.4%, or about 1 in 250 people without cancer.
• Sensitivity of 73.7% for the 12 cancers responsible for roughly two-thirds of all cancer deaths, but only around 40% across all cancer types combined — sensitivity varies enormously by cancer, from very high (liver, pancreatic) to very low (thyroid, and some early-stage cancers of any type).
• Positive predictive value of ~62% — roughly 6 in 10 people with a positive signal are ultimately confirmed to have cancer after diagnostic work-up.
• Cancer signal origin accuracy of ~92–93% — when a signal is detected, the predicted tissue of origin is correct in the large majority of cases, which materially shortens the diagnostic pathway.
• Adding the test to recommended screening increased overall cancer detection more than seven-fold in the trial population — but the majority of cancers detected were still found via standard screening, not the blood test alone.

Who should consider liquid biopsy screening

• Adults over 40–50 with no current cancer symptoms who want an additional layer of surveillance
• People with a family history of cancer — especially cancers with no existing population screening programme (pancreatic, ovarian, kidney, blood cancers)
• Executives and frequent travellers who want a proactive baseline as part of an annual health strategy
• Anyone already engaged in comprehensive preventive screening who wants their oncology surveillance to match the depth of their cardiovascular and metabolic panel

It is generally not intended for people already under active cancer surveillance or treatment, for whom a physician will direct the appropriate diagnostic pathway.

Where liquid biopsy fits in a prevention-first health strategy

At Aeonix, we think about prevention in layers, each building on the one below it:

1. Foundational biomarkers — 90 to 150+ markers across cardiovascular, metabolic, hormonal, nutritional, hepatic/renal, and haematological domains, included in every plan and tracked annually so your physician sees trends, not just single values.
2. Adjunct oncology markers — PSA (men) from Vital Edge upward, with CEA and AFP added from Longevity Plus upward. This layer is not included in Prime Health.
3. Multi-cancer signal screening (liquid biopsy) — the advanced layer, designed for people who want surveillance that extends beyond the handful of cancers standard tumour markers and organised screening already cover.

How the first two layers currently break down by plan:

If oncology surveillance matters to you specifically — for example, because of family history — Vital Edge and above are the plans built to include it today. Liquid biopsy is being introduced as the third, most advanced layer on top of that: an optional add-on for those who want the broadest possible view of their long-term cancer risk.

Coming soon: liquid biopsy through Aeonix's Zürich, Zug, and Basel lab partners

Aeonix is preparing to introduce liquid biopsy multi-cancer screening through laboratory partners in Zürich, Zug, and Basel — three of the markets where our existing biomarker panels, executive health, and longevity screening content already serve the largest share of clients. The rollout will follow the same principles as the rest of the Aeonix platform: physician-reviewed results, clear communication of what a result does and does not mean, and integration with your existing annual biomarker history rather than a stand-alone, context-free test.

Availability details, pricing, and lab partner names will be published on this page and across Aeonix's Zürich, Zug, and Basel content as the service launches. If you'd like to be notified when liquid biopsy screening becomes available in your city, join the Aeonix waitlist below.

Frequently asked questions

Worry about cancer, left unaddressed, tends to either fade into avoidance or harden into anxiety. A structured, physician-reviewed answer — repeated on a sensible schedule — is usually the healthier middle path.